Kowa obtains approval from MHLW for Rho kinase inhibitor as ocular hypertension therapeutic

In clinical trials with Japanese patients suffering from ocular hypertension and primary open-angle glaucoma, this agent was used in combination with existing therapies or alone. In any case, it showed effects in intraocular pressure reduction.

Kowa press release, Sept. 29, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny